Skip to main content
Andor Glaudemans
prof. dr.

I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.

Somatostatin receptor imaging by SPECT and PET in patients with chronic inflammatory disorders: a systematic review
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document 10.1007/s00259-019-04489-z document
OBJECTIVE: To review the literature on the clinical application of radiolabeled somatostatin receptor scintigraphy (SRS) by SPECT and PET in adults with chronic inflammatory diseases. RESEARCH DESIGN: Systematic review of published observational studies between 1993 and 2017. DATA COLLECTION AND ANALYSIS: The Cochrane Central Register of Controlled Trials, MedLine, EMBASE, PubMed, Google Scholar, OVID, EBSCO, Scopus, and Web of Science were used to search for studies on the use of SRS in adults with chronic inflammatory diseases. A team of reviewers independently screened for eligible studies. Quality of...
Luz Kelly Anzola, Andor W J M Glaudemans, Rudi A J O Dierckx, F Andres Martinez, Sergio Moreno, Alberto Signore
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization
Published in: Journal of Cardiac Failure
Access to document 10.1016/j.cardfail.2019.08.002 document
Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible. However, the diagnostic criteria and utilization of imaging in cardiac amyloidosis are not standardized. In this paper, Part 2 of a series, a panel of international experts from multiple societies define the diagnostic criteria for cardiac amyloidosis and appropriate utilization of echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in the evaluation of patients with known or suspected cardiac amyloidosis.
Sharmila Dorbala, Yukio Ando, Sabahat Bokhari, Angela Dispenzieri, Rodney H. Falk, Victor A. Ferrari, Marianna Fontana, Olivier Gheysens, Julian D. Gillmore, Andor W. J. M. Glaudemans, Mazen A. Hanna, Bouke P. C. Hazenberg, Arnt V. Kristen, Raymond Y. Kwong, Mathew S. Maurer, Giampaolo Merlini, Edward J. Miller, James C. Moon, Venkatesh L. Murthy, C. Cristina QuartaClaudio Rapezzi, Frederick L. Ruberg, Sanjiv J. Shah, Riemer H. J. A. Slart, Hein J. Verberne, Jamieson M. Bourque
Predictive Potential of Nonstandard Quantitative Imaging Features in Diabetic Foot
A. Marciano, J. Beukinga, Z. Keidar, M. Kurash, R. Zanca, A. W. J. M. Glaudemans, P. A. Erba, R. H. J. A. Slart
The association between bone mineral density and aortic calcification: the existence of a bone-vascular axis after renal transplantation
Camilo G. Sotomayor, Stan Benjamens, Antonio W. Gomes-Neto, Robert A. Pol, Andor W. J. M. Glaudemans, Stefan P. Berger, Stephan J. L. Bakker, Riemer H. J. A. Slart
Characterization of post-transplant lymphoproliferative disorder with semi-quantitative FDG-PET/CT
Aim/Introduction: One of the most dire complications of hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) is the development of post-transplant lymphoproliferative disorder (PTLD). PTLD compromises a broad spectrum of disorders classified by the 2017 World Health Organization (WHO) in non-destructive, polymorphic, monomorphic and classic Hodgkin lymphoma. Distinct morphologies are associated with a more favorable clinical course and better response to initial treatment. Reduction of immunosuppression, commonly used as first-line treatment, has been associated with higher response rates in non-destructive and polymorphic PTLD, while a more aggressive...
F. Montes De Jesus, W. Noordzij, X. Kahle, M. Nijland, E. Verschuuren, R. Dierckx, T. Van Der Meerten, W. Van Der Bij, G. Huls, T. Kwee, A. Glaudemans